Send us a textThis week we host Sam Ewing, who is the Global Head of Pharma Partnerships at Doccla. We speak about endpoint development in general - and digital endpoint development in particular. We define digital endpoints as something that happens in a patient's home, and is mediated by a smartphone with some technology associated with it. The benefits of digital endpoints for patients are tangible. They would not need to visit sites as often. That would make it easier to be a trial participant, and increase the diversity of clinical trial participants. That in turn would lead to better ecological validity of the data.We also speak about how a virtual ward is analogous to decentralised trials and how some of the data collected in a virtual ward setting could be used for clinical trials - potentially reducing the scale and complexity of clinical trials in the future.  Connecting the healthcare system and the clinical research setting could mean that we can re-use the data collected in one or the other setting.Guest:Samuel Ewinghttps://www.linkedin.com/in/samuelewing/Docclahttps://www.linkedin.com/company/doccla/ Notes:Digital endpoint approvalhttps://www.clinicalresearchnewsonline.com/news/2023/02/16/a-long-time-coming-on-digital-endpoints Digital Medicine Initiativehttps://dimesociety.org/Support the show________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn page

Ver todos los episodios